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Abstract
Multiclass-drug resistance, often caused by poor treat-
ment compliance, is a challenging problem in all cate-
gories of HIV-infected patients. Selective pressure is
higher in youth for both biological and behavioral rea-
sons. We report the case of a 15-year-old Caucasian
male, with vertically acquired HIV-1 infection, who
failed several lines of antiretroviral therapy and was
successfully treated with darunavir/ritonavir and
etravirine.
Key words: vertically acquired HIV-1 infection, multi-
drug resistance, adherence, darunavir, etravirine
INTRODUCTION
The use of highly active antiretroviral therapy
(HAART) has dramatically improved the quality of life
and overall survival of adults and children infected
with HIV-1. However, suboptimal exposure to
HAART (e.g. due to poor adherence, inadequate dose)
can rapidly select for drug resistance mutations, and
ultimately lead to virological failure. Given the dynam-
ics of HIV viral evolution, almost complete (>95%)
adherence to combination therapy is required to maxi-
mally suppress viral load and avoid selection of resis-
tant strains [1].
Moreover, children and adolescents seem to be
more prone to selection of drug resistant variants for
both biological and behavioral reasons. Plasma viral
loads are much higher in children compared to adults.
Therefore, children require more potent HAART to
achieve virological suppression [1]. Loss of adherence,
long lasting exposure to drugs and multi-drug resis-
tance can determine a more difficult scenario to man-
age a therapeutical failure than in adults.
CASE REPORT
We describe a 15-year-old Caucasian male, with verti-
cally acquired HIV-1 infection, who failed several lines
of antiretroviral therapies.
He was born premature, at 22nd week of gestation,
with a spontaneous delivery, to a mother who did not
assume any therapy during pregnancy. His father died
few months after his birth. He remained off medica-
tions until he was 1-year-old. He was started
monotherapy with zidovudine in 1993, didanosine in
1994, restarted zidovudine in 1995, and then was treat-
ed with stavudine in 1996. All antiretroviral therapies
were done without compliance by the mother-side and
were discontinued by her after some months. In 1997,
the patient started the first protease inhibitor (PI)-
based HAART with ritonavir plus zidovudine plus
lamivudine, without immuno-virological response. The
same happened with all the others regimens (Table 1).
I nt h ee n d ,h eh a df a i l e df o u rr i t o n a v i r - b o o s t e dP I -
based and one nevirapine-based HAART. The pa-
tient’s viral load had never been suppressed from his
birth, his CD4 cells count nadir was 67 cells/µl (5.4%)
and his viral load zenith was 89,700 copies/mL.
Plasma HIV-1 RNA was measured at baseline and
during therapy using a commercial assay, the Versant
HIV-1 RNA 3.0 Assay (bDNA; Siemens Medical Solu-
tions Diagnostics, Malvern, PA), with a dynamic range
of 50-500,000 HIV-1 RNA copies/mL. CD4 cells
count was determined by direct immunofluorescence
in flow cytometry (Beckman Coulter, Fullerton, CA).
Genetic analysis of the pol gene including both HIV-1
reverse transcriptase (codons 4-99) and protease
(codons 35-247) regions was performed using the Tru-
gene HIV-1 Genotyping Kit (Siemens Medical Solu-
tions Diagnostic).
In January 2008, his clinical conditions were good,
CDC status B2 (bacterial pneumonia), and height 167
cm, weight 54 kg, and body mass index (BMI) 19.36.
His viral load was 89,700 copies/mL and the CD4
cells count was 287 cells/µl (16%). The genotype re-
vealed the presence of D67N, K70R, Y181C, M184V,
T215F, K219Q mutations within transcriptase and
L10I, I13V, L24I, L33F, E34Q, M36L, F53L, I54V,
L63P, G73S, V82A, N83D mutations within protease
genes (Table 1). In summary, there were multiple drug
resistance (MDR) mutations, which conferred high-
level resistance to most currently available antiretrovi-
ral agents, included class-resistance to the non-nucleo-
side reverse transcriptase inhibitors (NNRTIs).
In that period there was also a change in his family
situation: the mother, who had been in jail for 6
months, was released and began to be compliant to
her therapy. Therefore, after deep counseling to him
and the mother, we decided to prescribe a new
HAART. Darunavir/ritonavir and etravirine were pro-
vided for compassionate use by Tibotec (Cork, Ire-
land) and their use was approved by San Martino Hos-
pital Ethical Committee (Genoa, Italy). The patient
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cavir/lamivudine combination. Based on the weight,
he could take the adult dose of each drug.
After one month of therapy, viral load became un-
detectable for the first time in the patient’s life. During
the first year of follow-up, viral load remained stably
undetectable, meanwhile CD4 cells count and percent-
age increased to 706 cells/mL and 18%, respectively.
Laboratory data remained within normal range show-
ing no hepatic and metabolic toxicity. In particular,
median aspartate aminotransferase (AST, normal
range, r, 0-40) was 33 U/L, alanine aminotransferase
(ALT, r 0-40) 23 U/L, γ glutamyltranspeptidase (GGT,
r 11-50) 28 U/L, plasma glucose (r 65-110) 83 mg/dL,
glycated haemoglobin (r 4.3-5.8) 5.1%, insulin levels (r
2.0-25) 5.8 mU/L, triglycerides (r 4-170) 110 mg/dL,
total cholesterol (r 130-200) 177 mg/dL, HDL-choles-
terol 31.5 mg/dL, and LDL-cholesterol 118 mg/dL.
The new regimen was well tolerated and adherence
to treatment was reported excellent throughout the
entire period, monitored by performing monthly out-
patient’s visit and calling the patient every two weeks.
DISCUSSION
Strategies for the management of HIV-infected pa-
tients with extensive previous treatment and drug re-
sistance are very limited, especially in children and
adolescents. As a matter of fact, in this population the
use of experimental agents, with a close follow-up,
must be considered. Besides, a careful monitoring of
adherence is needed for a successful therapy.
This case report has examined the successful inhibi-
tion of viral replication in a MDR patient who exhibit-
ed very poor compliance with previous therapies. The
treatment regimen consisted of a new and recently ap-
proved combination used in adults, based on
darunavir/ritonavir and etravirine, in addition to a
well-known nucleoside reverse transcriptase inhibitor
backbone [2]. In the first year of therapy the CD4
cells count increased and viral load fell to undetectable
levels. Tolerability was good and no serious adverse
events were recorded. The patient is still following this
regimen.
This antiretroviral regimen has been chosen in con-
sequence of the poor compliance of the patient
showed during the past years. Fixed dose aba-
cavir/lamivudine combination was used as backbone.
Abacavir seemed to maintain a partial activity, at least
according to some interpretation alghorithms, and was
preferred to tenofovir which would have been a safer
choice based on mutational pattern, by reason of pre-
viously tested poor tolerability (proteinuria). Lamivu-
dine was maintained in order to affect viral fitness.
Darunavir, in combination with low-dose ritonavir,
approved in adult since July 2007 in Italy, has shown
potent antiviral activity and good tolerability in three-
class-experienced HIV-infected patients with limited
EUROPEAN JOURNAL OF MEDICAL RESEARCH March 17, 2009 137
Table 1. Summary of HAART regimens and genotypic resistance tests of the patient
Legend: r: ritonavir; GRT: genotypic resistance test; RTRM: reverse transcriptase mutations; PIRM: protease mutations.
Antiretroviral Therapy Start End VL CD4+ CD4+(%) Reason of change
Zidovudine 15/11/93 09/12/93 N.A. 1196 23,2 no compliance
Didanosine 10/12/93 28/04/94 N.A. 1328 24,2 no compliance
Zidovudine 01/07/95 07/06/96 N.A. 316 13,2 no compliance
Stavudine 28/06/96 27/02/97 1000 67 5,4 no compliance
Zidovudine + lamivudine 28/02/97 02/09/97 27000 103 8,2 virological failure
Zidovudine + lamivudine 03/09/97 20/03/98 2200 251 14,2 virological failure
+r i t o n a v i r
Didanosine + nelfinavir 12/10/98 15/07/01 248 129 5,6 virological failure
+s a q u i n a v i r
Stavudine + didanosine 24/07/01 23/06/04 45000 259 14 virological failure
+ lopinavir/r
Didanosine + tenofovir 24/06/04 09/03/05 2800 644 22 virological failure
+ lopinavir/r
Didanosine + tenofovir 10/03/05 10/11/05 7700 465 20 virological failure
+ nevirapine
GRT: RTRM: D67N, K70R, V106A, Y181C, T215F, K219Q, F227L; PIRM: L10I, L24I, L33F, M36I/L, I54V, L63P, V82A
Abacavir + lamivudine 11/11/05 11/04/07 19600 334 17 no compliance
+ Fos-Amprenavir/r
GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, L24I, L33F, M36L, F53L I54V, L63P, G73S, V82A
Abacavir + lamivudine 12/04/07 12/02/08 14800 410 17 virological failure
+ lopinavir/r
GRT: RTRM: D67N, K70R, Y181C, M184V, T215F, K219Q; PIRM: L10I, I13V, L24I, L33F, M36L, F53L, I54V, L63P, G73S,
V82A
Abacavir + lamivudine 13/02/08 ongoing 89700 287 16 ongoing
+ darunavir/r + etravirineor no treatment options [3]. Recent reports have high-
lighted that 11 mutations of which 5 major (I50V,
I54L/M, L76V and I84V) and 6 minor (V11I, V32I,
L33F, I47V, G73S and L89V), selected in patients fail-
ing it, are associated with decreased susceptibility to
darunavir [4].
In our patient the presence of three minor muta-
tions (L33F, G73S and L89V) had not compromised
the efficacy of the drug. This fact, probably, confirms
the importance of number, type, pattern of associa-
tion and weight of mutations.
Etravirine, currently available in Italy only in the ex-
panded access program (TMC125-c214), is a second
generation NNRTI that appears to be effective against
a variety of HIV viruses that are resistant to efavirenz
and nevirapine. Three or more mutations are associat-
ed with decreased virologic response [5]. In our pa-
tient there was only one mutation (Y181C), but with a
weight factor of 2.5, using the weighted genotypic
score. This score has been provided by Vingerhoets J
et al. analyzing the database of the patients enrolled in
the DUET-1 and DUET-2 trials [6]. The sum of the
different weighted factors predicts virological re-
sponse to etravirine, and in our patient this should
have been an intermediate response.
One of the first studies, assessing the role of
etravirine and darunavir in HIV-1-infected subjects
with no treatment options, showed highly effective vi-
rological and immunological responses over 24 weeks
of therapy with no new safety concerns or unexpected
pharmacokinetic interactions [7].
Enfuvirtide could be another good choice, also be-
cause it is approved for pediatric use, but its way of
administration, with often-intolerable subcutaneous
injection site reactions, would have never been accept-
ed from the patient. The genotypic test showed also
a susceptibility to tipranavir (one major I54V and
one accessory mutation L33F), confirmed from the
tipranavir-mutation-score (Score=1) that could allow
us to choose that drug in the new regimen [8]. We de-
cided, however, to choose darunavir, because
etravirine should not be administered with tipranavir
[9].
In conclusion, this case report underlines the im-
portance of the continuous development of new
drugs and the great need of their approval also for pe-
diatric/adolescent use, as clinicians will continue to
encounter an increasing number of MDR HIV-infect-
ed youths, who have extensive experience with previ-
ous treatments. It is, indeed, of extreme importance to
evaluate the compliance with all the available methods
(e.g. self reporting calendars, records of missed doses,
pill counts, interview questionnaires, therapeutic drug
monitoring), knowing that the most common cause of
treatment failure is insufficient adherence, which can
be found in 25-30% of children [10].
In particular, adolescents with vertically acquired-
HIV- infection may require complicated regimens, be-
cause of significant antiretroviral treatment experience
and poor adherence.
So it is clear the importance of having parents
and/or caregivers who can do an accurate and consis-
tent monitoring and improve the children/adolescent’s
compliance.
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